{"filing":{"accession_number":"0001193125-26-346856","cik":"0001422143","ticker":"KURA","company_name":"Kura Oncology, Inc.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"kura-20260812.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526346856/kura-20260812.htm"},"events":[{"id":27198,"run_id":24771,"accession_number":"0001193125-26-346856","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing Kura Oncology's second quarter 2026 financial results, including net product revenue of $9.1 million, collaboration revenue of $11.8 million, R\u0026D expenses of $61.9 million, and a net loss of $68.3 million. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The filing includes detailed financial statements and operational metrics for the quarter ended June 30, 2026.","company_name":"Kura Oncology, Inc.","ticker":"KURA","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28621,"accession_number":"0001193125-26-346856","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Kura Oncology's second quarter 2026 financial results, including net product revenue of $9.1 million, collaboration revenue of $11.8 million, R\u0026D expenses of $61.9 million, and a net loss of $68.3 million. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The filing includes detailed financial statements and operational metrics for the quarter ended June 30, 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:15:10.604079+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28621,"accession_number":"0001193125-26-346856","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Kura Oncology's second quarter 2026 financial results, including net product revenue of $9.1 million, collaboration revenue of $11.8 million, R\u0026D expenses of $61.9 million, and a net loss of $68.3 million. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The filing includes detailed financial statements and operational metrics for the quarter ended June 30, 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:15:10.604079+00:00","company_name":"Kura Oncology, Inc.","ticker":"KURA","filing_date":"2026-08-12"}]}